Nevertheless, the activation of PI3K/AKT/mTOR pathway in glioma leads to the development of drug resistance, thereby inhibiting the therapeutic effect of “T” (Li et al., 2016; Xia et al., 2020). This evidence concerns the gene MTOR and central nervous system cancer.